Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1/2a study of BMS-986528 in refractory rheumatoid arthritis
2025-520666-22-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of BMS-986528 in rheumatoid arthritis (RA), sponsored by Bristol Myers Squibb. Primary endpoint: Safety and tolerability. Planned start Jul 2026; status: authorised.
02
Drugs
BMS-986528
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2025-520666-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520666-22-00.